Dubois R, Abramson S, Crofford L. Cyclooxigenase in biology and disease. Faseb J.. 1998;12:1063-1088.

Tilley Sl, Coffman TM, Koller BH. Mixed messages modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001;108:15-23.

Gottschalk A, Smith DS. New concepts in acute pain therapy: preemptive analgesia. Am Fam Physician. 2001;63:1979-1984.

Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971;231:232-235.

Dahl V, Aeder JC. Non-opioid postoperative analgesia. Acta Anaesthesiol Scand. 2000;44:1191-1203.

Yaksh TL, Dirig DM, Conway CM. The acute antihy- peralgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosc. 2001;21:5847-5853.

Souter AJ, Fredman B, White PF. Controversies in the perioperative use of nonsteroidal antiinflamatory drugs. Anesth Analg. 1994;79:1178-1190.

Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional nosteroidal anti-inflammatory drugs. Am J Med. 2001;111:64-67.

Brooks P, Emery E, Evans F. Interpreting the clinical significance of the diferential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology. 1999;38:779-788.

Marnett LJ, Rowlinson WS, Goodwin DC. Arachidonic acid oxygenation by COX-1 and COX-2. J Biol Chem. 1999;274:22903-22906.

Jones R. Nonsteroidal Anti-inflamatory drug prescribing: past, present and future. Am J Med. 2001;110:4s-7s.

Fitzgerald GA, Patrono C. The coxibs, selective inhibitor of cyclooxygenase-2. N Engl J Méd. 2001;345:433-442.

Harris RC, Breyer MD. Physiological regulation of cyclo- oxygenase-2 in the kidney. Am J Physiol Renal Physiol. 2001;281:F1-F11.

Schonbeck U, Sukhova GK, Graber P. Augmented expression of COX-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.

Reddy ST, Herschman HR. Transcellular prostaglandin production following mast cell activation is mediated by proximal secretory phospholipase A2 and distal prostaglandin synthase-. J Biol Chem. 1996;271:186-191.

Lipsky PE. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med. 2000;160:913-920.

Beejay V, Wolfe MM. Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan?. Gastroenterology. 1999;117:1002-1005.

Willoughby DA, Moore AR, Colville-Nash PR. - COX-1, COX-2, and COX-3 and the future of chronic inflammatory disease. Lancet. 2000;355:646-648.

Pairet M, Van Ryn J. Experimental models used to investigate the diferential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res. 1998;47:s93-s101.

Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2 specifec inhibitors. Am J Med. 2001;110:33s-42s.

Chan CC, Boyce S, Brideau C. Rofecoxib [VIOXX, MK-0966,4-(4´methylsulfonylphenyl)-3-phenyl-2-(5H)- furanone]: a potent and orally active cyclooxygenase-2 inhibitor-pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999;290:551-560.

Cannon Gw, Breedveld FC. Efficacy of cyclooxygenase-2 specific inhibitors. Am J Med. 2001;110:6s-12s.

Jain KK. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Expert Opin Investig Drugs. 2000;9:2717-2723.

Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs. 2001;61:1133-1141.

Lee A, Cooper MG, Craig JC. Effects of nonsteroidal anti-inflammatory drugs on post-operative renal function in adults. Cochrane Database Syst Rev. 2000;4.

Harris CJ, Brater DC. - Renal effects of cyclooxygenase 2 selective inhibitors. Curr Opin Nephrol Hypertens. 2001;10:603-610.

Wang JL, Cheng HF, Harris RC. Cyclooxygenase inhibition decreases rennin content and lowers blood pressure in a model of renovascular hypertension. Hypertension. 1999;34:96-101.

Wolf K, Castrop H, Hartner A. Inhibition of the rennin-angiotensin system upregulates cyclooxygenase-2 expression in the macula densa. Hypertension. 1999;34:503-507.

Yang T, Schnermann JB, Briggs JP. Regulation of cyclo- oxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol Renal Physiol. 1999;277:F1-F9.

Hao CM, Yull F, Blackwell T. Dehydration activates an NF-kB-driven: COX-2 dependent survival mechanism in renal medullary intesticial cells. J Clin Invest. 2000;106:973-982.

Cowley A, Mattson D, Lu S. The renal medulla and hypertension. Hypertension. 1995;25:663-673.

Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2 inhibition. Am J Med. 1999;107:65s-70s.

Komhoff M, Wang JL, Cheng HF. Cyclooxygenase-2 selective inhibitors impair glomerulogenesis and renal cortical development. Kidney Int. 2000;57:414-422.

Nantel F, Meadows E, Denis D. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS letters. 1999;457:475-477.

Rocha JL, Férnandez-Alonso J. Acute tubulointersticial nephritis associated with the selective COX2 enzyme inhibitor, rofecoxib. Lancet. 2001;357:1946-1947.

Buttgereit F, Burmester GR, Simon LS. Gastrointestinal toxic side effects of nonsteroidal antiiflammatory drugs and cyclooxygenase-2 specific inhibitors. Am J Med. 2001;110:13s-19s.

Emery P. Cyclooxygenase-2: A major therapeutic advance?. Am J Med. 2001;110:42s-45s.

Eckmann L, Stenson C, Matsuda K. Induction of intestinal epithelial cells in the host secretory response to infection by invasive bacteria: bacterial entry induces epithelial prostaglandin H synthase-2 expression and prostaglandin E2 and F2α production. J Clin Invest. 1997;100:269-309.

Schnitzer TJ. Cyclooxygenase-2 specific inhibitors: Are they safe?. Am J Med. 2001;110:46s-49s.

Patrono C. Aspirin as an antiplatelet drug. N Eng J Med. 1994;330:1287-1294.

Rodriguez-Tellez M, Arguelles F, Herrerias JM. Antiiniflammatory agents less dangerous for gastointestinal tract. Current Pharm Des. 2001;7:951-976.

Yeomans ND. New data on healing of nonsteroidal anti-inflammatory drug associated ulcers and erosion: omeprazole NSAID steering committee. Am J Med. 1998;104:56s-61s.

O´Beirne JP, Cairns SR. Cholestatic hepatitis in association with celecoxib. Br Med J. 2001;323:23.

Maddrey WC, Maurath CJ, Verburg KM. The hepatic safety and tolerability of the novel cyclooxygenase inhibitor celecoxib. Am J Ther. 2000;7:153-158.

Carillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis. Arch Intern Med. 2000;170:553-554.

Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides?: Revisiting the meaning of "sulfa" allergy. Drug Saf. 2001;24:239-247.

Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001;110:28s-32s.

Wijeyaratne SM, Abbott CR, Homer-Vanniasinkam S. Differences in the detection of cyclo-oxygenase 1 and 2 proteins in symptomatic and asymptomatic carotid plaques. Br J Surg. 2001;88:951-957.

Hawkey CJ, Lanas AI. Doubt and certainty about NSAID in the year 2000: a multidisciplinary expert statement. Am J Med. 2001;110:79s-100s.

Lipsky PE. Recommendations for the clinical use of cyclooxygenase-2-specific inhibitors. Am J Med. 2001;110:3s-5s.

Boers M. NSAIDS and COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet. 2001;357:1222-1223.

Karplus TM, Saag KG. Nonsteroidal anti-inflammatory drugs and cognitive function: have a beneficial or deleterious effect?. Drug Saf. 1998;19:427-433.

Norwitz ER, Robinson JN, Challis JR. The control of labor. N Engl J Med. 1999;341:660-666.

Sawdy R, Slater D, Fisk N. Use of a cycoloxygenase type -2 selective non-steroidal anti-inflammatory agent to preent preterm delivery. Lancet. 1997;350:265-266.

Peruzzi L, Glanogllo B, Porcellinni MG. Neonatal end-stage renal failure associated with maternal ingestion of COX-2 selective inhibitor nimesulide as tocolytic. Lancet. 1999;354(9190):1615.

Sjodahl R. Extent, mode and dose dependence of anticancer effects. Am J Med. 2001;110:66S-69S.

Myers C, Koki A, Pamukcu R. Proapoptotic anti-inflammatory drugs. Urology. 2001;57:73S-75S.

Khan KN, Masferrer Jl, Woerner BM. Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scan J Gastroenterol. 2001;36:865-869.

Steibach G, Lynch PM, Phillips R. Effect of celecoxib on colorectal polyposis (FAP). Am Gastroenterol. 1999;94:A440.